|
WO2018053040A1
|
|
Treatment of multiple sclerosis with chs-131
|
|
KR20190064573A
|
|
PPARγ agonists for the treatment of blood cancer
|
|
AU2017313842A1
|
|
PPARgamma AGONIST FOR TREATMENT OF BONE DISORDERS
|
|
MX2019001981A
|
|
Pparï’ agonist for treatment of bone disorders.
|
|
MX2017011586A
|
|
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy.
|
|
KR20150133182A
|
|
Pparγ agonists for treatment of multiple sclerosis
|
|
CA3029948A1
|
|
Antidiabetic solid pharmaceutical compositions
|
|
WO2010040055A2
|
|
Oral pharmaceutical formulations for antidiabetic compounds
|
|
WO2009111078A2
|
|
Combination of a ppary agonist and a dipeptidyl peptidase-inhibitor for the treatment of diabetes and obesity
|
